NCT01085123View on ClinicalTrials.gov

Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Migraine
Interventions
DRUG

Rapimelt

oral tablet , 2.5 and 5 mg, single dose. 10 mg (2x5 mg) visit 3, 5 mg visit 4, 2.5 mg visit 5.

DRUG

[11C]AZ10419369

solution for iv injection. Will be injected within 2 to 5 hours after administration of ZOMIG® Rapimelt

Trial Locations (1)

Unknown

Research Site, Uppsala

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY